Abstract Purpose: Gemtuzumab ozogamicin (Mylotarg; Wyeth Laboratories, Philadelphia,
PA) consists of a semisynthetic derivative of calicheamicin, a cytotoxic antibiotic linked to a …

Introduction: Gemtuzumab ozogamicin (GO) is an antibody-drug conjugate consisting of a
monoclonal antibody targeting CD33 linked to a cytotoxic derivative of calicheamicin …

Among the few drugs that have shown a benefit for patients with acute myeloid leukemia
(AML) in randomized clinical trials over the last several decades is the CD33 antibody-drug …

Gemtuzumab-ozogamicin (GO) is an antibody-drug conjugate (ADC) in which a monoclonal
antibody targeting CD33 is covalently linked to the toxin calicheamicin. GO was initially …

Gemtuzumab ozogamicin (Mylotarg®) is an immunoconjugate composed of a recombinant
humanized murine anti-CD33 antibody linked to calicheamicin, a potent cytotoxic agent. The …

Abstract On 1 September 2017, the US Food and Drug Administration (FDA) approved
gemtuzumab ozogamicin (GO) for the treatment of adults with newly diagnosed CD33+ …

Introduction Acute myeloid leukemia (AML) is the most common and deadly type of leukemia
affecting adults. It is typically managed with rounds of non-targeted chemotherapy followed …

Background Previous trials demonstrated evidence involving the total effects of gemtuzumab
ozogamicin (GO), an anti-CD33 humanized antibody, on treating acute myeloid leukemia …

CD33 is variably expressed on leukemia blasts in almost all patients with acute myeloid
leukemia (AML) and possibly leukemia stem cells in some. Efforts to target CD33 …

Gemtuzumab ozogamicin (GO) is a recently developed antibody‐targeted chemotherapeutic
agent and has been expected to be less toxic than conventional chemotherapy. We …